EMAIL THIS PAGE TO A FRIEND

Oncotarget

MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells.


PMID 29190894

Abstract

BCR-ABL-independent resistance against tyrosine kinase inhibitor is an emerging problem in therapy of chronic myeloid leukemia. Such drug resistance can be linked to dysregulation of ATP-binding cassette (ABC)-transporters leading to increased tyrosine kinase inhibitor efflux, potentially caused by changes in microRNA expression or DNA-methylation. In an